Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 4 No. 1 (1998)

The Use of AZT to Reduce the Risk of Vertical Transmission of Human Immunodeficiency Virus

  • V. Bhargavi Rao, B.A.
November 8, 2020




  1. Gayle H. Epidemiology of HIV infection, with a focus on mother-to-child transmission and among drug users. Current Opinions in Infectious Diseases 6: 200-204; 1993.
  2. Banatvala JE, O’Shea S, Newell ML, et al. Studies on HIV infected women and their infants. Research fund proposal; 1995.
  3. Fowler MG, Rogers MF. Overview of perinatal HIV infection. Journal of Nutrition 126: 2602S - 2607S; 1996.
  4. Rogers MF, Jaffe HW. Reducing the risk of maternal-infant transmission of HIV: a door is opened. New England Journal Of Medicine 331: 1222-1223; 1994.
  5. Thisyakorn U, Ruxrungtham K, Phanuphak P. HIV and AIDS Current Trends 4: 1-3; 1998.
  6. Gerold M., Adler R. Manifestations of pediatric AIDS: proposed mechanisms for transmission. Medical Hypotheses 37: 205-212; 1992.
  7. Sager P. Conference report: workshop on the role of the placenta in HIV infection and therapy - Nantucket, Massachusetts, September 1990. Placenta 12: 669-672; 1991.
  8. Newell ML. European collaborative study - risk factors for vertical transmission. European Collaborative Study Conference Report; 1992: 6-13.
  9. Connor EM, Sperling RS, Gelber R. et al. Reduction of maternal-infant transmission of the human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine 331: 1173-1180; 1994.
  10. Clinical Alert. Important therapeutic information on the benefit of zidovudine for the prevention of the transmission of HIV from mother to infant. ACTG Site Instruction Package; 1994.
  11. Connor EM, Mofenson LM. Zidovudine for the reduction treatment of perinatal human immunodeficiency virus transmission: pediatric AIDS clinical trials group 076 - results and treatment recommendations. Pediatric Infectious DiseaseJournal 14: 125-131; 1995.
  12. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1. JAMA 271: 1925-1930; 1994.
  13. Matheson PB, Abrams EJ, Thomas PJ, et al. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. Journal of InfectiousDiseases 172: 353-358; 1995.
  14. Cooper E, Diaz D, Pitt J, et al. Impact of ACTG076: use of idovudine (ZDV) during pregnancy and changes in the rate of HIV vertical transmission. 3rd Conference of Retro and Opportunistic Infectection 57; 1996.
  15. Whiting RB. The response of state health departments and national associations to the results of ACTG 076. International Conference on AIDS 11: 410; 1996.
  16. Simpson BJ, Shapiro ED, Andiman WA, et al. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14: 145-152; 1997.
  17. Martinez-Tejada B. Zidovudine prophylaxis for the prevention of HIV vertical transmission in the hospital clinic of Barcelona. International Conference on AIDS 11: 77; 1996.
  18. Cahn P. Zidovudine (ZDV) for prophylaxis of perinatal transmission starting on week 24. 4th Conference on Retroviruses and Opportunistic Infections 159; 1997.
  19. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. Journal of Infectious Diseases 163: 226-232; 1991.
  20. O’Sullivan MJ, Boyer PJ. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with the Human Immunodeficiency Virus and their infants - Phase I ACTG 082. American Journal of Obstetrics and Gynaecology 168: 1510-1516; 1993.
  21. Liebes L, Mendoza S, Wilson D, et al. Transfer of zidovudine (AZT) by the human placenta. Journal of Infectious Diseases 161: 203-207; 1990.
  22. Liebes L, Mendoza S, Lee JD, et al. Further observations on zidovudine transfer and metabolism by the human placenta. AIDS 7: 590-592; 1993.
  23. Pons JC, Tabuset AM, Singlas E, et al. Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling. European Journal of Obstetrics and Gynaecology and Reproductive Biology 40: 229-31; 1991.
  24. Gillet JY, Garraffo R, Abrar D, et al. Fetoplacental passage of zidovudine. Lancet (2): 269-270; 1989.
  25. Bui T, Bark D, Perkins M, et al. Effect of zidovudine on human placental trophoblast and Hofbauer cell functions. Journal of AIDS 6: 120-126; 1993.
  26. Mofenson LM. Timing and mechanisms of HIV vertical transmission: implications for prevention. Archives of STD/HIV Research 7: 207-211; 1993.
  27. European collaborative study. Risk factors for mother to child transmission. Lancet 339: 1007-1012; 1992.
  28. The HIV Infection in Newborns French Collaborative Study Group. Comparison of vertical HIV type 2 and HIV type 1 transmission in the French prospective cohort. Pediatric Infectious Diseases 13: 502-506; 1994.
  29. Dunn DT, Newell ML, Ades AE, et al. Risk of HIV type 1 transmission through breastfeeding. Lancet 340: 585-588; 1992.
  30. Minkoff H, Burns D, Landesman SH. The relationship of the duration of ruptured membranes to vertical transmission of HIV. American Journal of Obstetrics and Gynaecology 173: 585-589; 1995.
  31. Scarlatti G, Albert J, Rossi P, et al. Comparison of variable region 3 sequences of HIV type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proceedings of the National Academy of Science (USA) 90: 1721-1725; 1993.
  32. Sperling RS, Shapiro D, Coombs RW, et al. Maternal viral load, zidovudine treatment and the risk of transmission of HIV type 1 from mother to infant. New England Journal of Medicine 335: 1621-1629; 1996.
  33. O’Shea S, Newell ML, Dunn DT, et al. Maternal viral load, CD4 cell count and vertical transmission of HIV-1. Journal of Medical Virology 54: 113-117; 1998.
  34. Minkoff H, Mofenson LM. The role of obstetric interventions in the prevention of pediatric HIV infection. American Journal of Obstetrics and Gynaecology 171: 1167-1173; 1994.
  35. Ho DD, Moudgil T, Alam M, et al. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. New England Journal of Medicine 321: 1621-1625; 1989.
  36. Henin Y, Mandelbrot L, Henrion R, et al. Virus excretion in the cervicovaginal secretions of pregnant and non-pregnant HIV- infected women. Journal of AIDS 6: 72-75; 1993.
  37. Burton GJ, O’Shea S, Rostron T, et al. Physical breaks in the placental trophoblastic surface: significance in vertical transmission. AIDS 10: 1294-1296; 1996.
  38. Kesson AM, Fear WR, Williams L, et al. HIV Infection of Placental Macrophages: their potential role in vertical transmission. Journal of Leukocyte Biology 56: 241-246; 1994.
  39. Lewis SH, Reynolds-Kohler C, Fox ME, et al. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in 8-week foetuses. Lancet 335: 565-568; 1990.
  40. Furman PA, Fyfe JA, St. Clair MH, et al. Phosphorylation of 3’- azido-3’-deoxythymidine and selective interaction of the 5’-triphosphate with HIV Reverse Transcriptase. Proceedings of the National Academy of Science (USA) 83: 8333-8337; 1986.
  41. Kumar RM, Hughes PF, Khurrana A, et al. Zidovudine use in pregnancy: a report of 104 cases and the occurrence of birth defects. Journal of AIDS 7: 1034-1039; 1994.
  42. Case control study of HIV seroconversion in health care workers after percutaneous exposure to HIV infected blood - France, United Kingdom, and United States, Jan 1988 - August 1994. Morbidity Mortality Weekly Report 44: 929-933; 1995.
  43. Le Grand R, Clayette P, Noack O, et al. An animal model for antilentiviral therapy: effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Research and Human Retroviruses 10: 1279-1287; 1994.
  44. Van Rompay KKA, Otsyola MG, Marthas ML, et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrobial Agents and Chemotherapy 39: 125-131; 1995.
  45. Bayer R. Ethical challenges posed by Zidovudine treatment to reduce vertical transmission of HIV. New England Journal of Medicine 331: 1223-1225; 1994.
  46. Meda N, Msellati P, Welflens-Ekra C, et al. The reduction of mother-child transmission of HIV infection in developing countries: potential intervention strategies, obstacles to implementation and perspectives. Sante 7:115-125; 1997.
  47. Hoffman CA. Ethical issues in the use of zidovudine to reduce vertical transmission of HIV. New England Journal Of Medicine 332: 891-892; 1995.
  48. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. Morbidity Mortality Weekly Report 47: 151-154; 1998.


Download data is not yet available.